Foresite Capital Management Iv, LLC Insmed Inc Transaction History

Foresite Capital Management Iv, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$14.11 - $29.42 $9.57 Million - $20 Million	-678,322 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$13.63 - $33.98 $10.2 Million - $25.5 Million	-751,196 Reduced 52.55%	678,322 $10.9 Million
Q3 2019 Nov 13, 2019	SELL	$15.49 - $25.78 $2.04 Million - $3.39 Million	-131,667 Reduced 8.43%	1,429,518 $25.2 Million
Q2 2019 Aug 13, 2019	BUY	$23.0 - $32.19 $627,946 - $878,851	27,302 Added 1.78%	1,561,185 $40 Million
Q1 2019 May 14, 2019	SELL	$13.91 - $31.15 $6.17 Million - $13.8 Million	-443,353 Reduced 22.42%	1,533,883 $44.6 Million
Q4 2018 Feb 13, 2019	BUY	$11.6 - $18.7 $2.05 Million - $3.3 Million	176,649 Added 9.81%	1,977,236 $25.9 Million
Q2 2018 Aug 14, 2018	BUY	$20.0 - $29.72 $27,240 - $40,478	1,362 Added 0.08%	1,800,587 $42.6 Million
Q1 2018 May 15, 2018	BUY	$21.69 - $32.99 $19.9 Million - $30.3 Million	919,315 Added 104.48%	1,799,225 $40.5 Million
Q4 2017 Feb 13, 2018	BUY	$26.43 - $31.78 $23.3 Million - $28 Million	879,910	879,910 $27.4 Million

466

180M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.35B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iv, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iv, LLC with notifications on news.